The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hyperferritinemia as predictive biomarker of poor clinical outcomes in CMML.
 
Luis E. Aguirre
No Relationships to Disclose
 
Somedeb Ball
No Relationships to Disclose
 
Akriti Gupta Jain
No Relationships to Disclose
 
Najla Al Ali
No Relationships to Disclose
 
David Andrew Sallman
Consulting or Advisory Role - Abbvie; Bluebird Bio; Bristol-Myers Squibb; Gilead Sciences; Intellia Therapeutics; Janssen; Kite, a Gilead company; Magenta Therapeutics; Molecular Partners; Novartis; Servier; Shattuck Labs; Syndax; Syros Pharmaceuticals; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Incyte; SERVIER
Research Funding - Aprea Therapeutics (Inst); Jazz Pharmaceuticals
 
Andrew T. Kuykendall
Leadership - Protagonist Therapeutics
Honoraria - Abbvie; BluePrint Research Group; Celgene/Bristol-Myers Squibb; CTI BioPharma Corp; Novartis; PharmaEssentia
Consulting or Advisory Role - Incyte; Protagonist Therapeutics
Speakers' Bureau - Blueprint Medicines; Celgene/Bristol-Myers Squibb; Novartis
Research Funding - Prelude Therapeutics; Protagonist Therapeutics
 
Kendra Lynn Sweet
Honoraria - Astellas Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis
Research Funding - Incyte (Inst)
 
Jeffrey E. Lancet
Stock and Other Ownership Interests - Arvinas (I)
Consulting or Advisory Role - Abbvie; BerGenBio; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; ElevateBio; Jazz Pharmaceuticals; Millennium; Novartis; Servier/Pfizer
 
Eric Padron
Honoraria - Blueprint Medicines; Stemline Therapeutics; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Kura Oncology (Inst)
 
Rami S. Komrokji
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Abbvie; Acceleron Pharma; Bristol-Myers Squibb; Geron; Jazz Pharmaceuticals; Novartis
Speakers' Bureau - Agios; Bristol-Myers Squibb; Jazz Pharmaceuticals
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Jazz Pharmaceuticals